Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2010 (2010), Article ID 390643, 8 pages
http://dx.doi.org/10.1155/2010/390643
Review Article

Mesoglycan: Clinical Evidences for Use in Vascular Diseases

Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, AOU “Federico II” Naples 80131, Italy

Received 1 March 2010; Revised 4 June 2010; Accepted 12 July 2010

Academic Editor: Alun H. Davies

Copyright © 2010 Antonella Tufano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease. The protective effect of mesoglycan in patients with venous thrombosis and the absence of side effects, support the use of GAG in patients with chronic venous insufficiency and persistent venous ulcers, in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation treatment.